MedPath

Coregistration of 18F-FDG-PET and MRI in the Staging of Potentially Resectable Hilar Cholangiocarcinoma: a Pilot Study

Withdrawn
Conditions
Cholangiocarcinoma
Registration Number
NCT00604266
Lead Sponsor
University of Toronto
Brief Summary

To evaluate the feasibility and performance of coregistered 18F-FDG-PET/MRI in the staging of potentially respectable hilar cholangiocarcinoma.

Detailed Description

Not available

Recruitment & Eligibility

Status
WITHDRAWN
Sex
All
Target Recruitment
Not specified
Inclusion Criteria
  • Hilar cholangiocarcinoma assessed by conventional imaging modalities (triphasic CT scan of the liver) and thought to be potentially resectable.
Read More
Exclusion Criteria
  • Biliary drain inserted.
  • Contraindication for MRI.
  • Pregnant or breast-feeding.
  • Uncontrolled diabetes (over 9.7 mmol/L).
Read More

Study & Design

Study Type
OBSERVATIONAL
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Secondary Outcome Measures
NameTimeMethod

Trial Locations

Locations (1)

UHN - Princess Margaret Hospital

🇨🇦

Toronto, Ontario, Canada

© Copyright 2025. All Rights Reserved by MedPath